Skip to Content

Varubi Approval History

Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.

Development History and FDA Approval Process for Varubi

Oct 25, 2017Approval Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy
Sep  2, 2015Approval FDA Approves Varubi (rolapitant) for Chemotherapy-Induced Nausea and Vomiting
Sep  8, 2014Tesaro Announces Submission of Rolapitant NDA to U.S. Food and Drug Administration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.